Galenica Expands Swiss OTC Offering Through Hedoga Acquisition
Galenica has reinforced its position as the leading player in the Swiss OTC market through the acquisition of Hedoga Group,
You may also be interested in...
Galenica struggled to keep up with OTC market growth in Switzerland as the COVID-19 outbreak severely hampered its sales in the opening six months of the year.
Launching skin-care products that blend "natural medicinal plants from the Swiss pharmacopoeia with the best Swiss skin science" helped to drive up Galenica's OTC sales in 2019 at a double-digit rate.
Galenica's Verfora took the lead in the Swiss consumer health market for the first time ever in 2018, ahead of its multinational rivals. But the firm is not stopping there. It has acquired a stake in local complementary medicines player Spapyros to take a slice of the poplar homeopathy market.